Member Info for imac1

liquid did you miss my post earlier on today regarding the email?

Here is what was said about the Covid 19 trial

4D's Chief Scientific Officer, Alex Stevenson, commented:
If MRx-4DP0004 is successful in this study it would represent a highly significant breakthrough in the global fight against the novel coronavirus pandemic."

Dr. Dinesh Saralaya (Consultant Respiratory Physician and Associate Director of Research at Bradford Teaching Hospitals NHS Foundation Trust, and the National Institute for Health Research's (NIHR) Clinical Lead for Respiratory industry studies), commented:
"As well as its appropriate mechanism of action, the highly favourable safety profile of MRx-4DP0004 makes it a particularly attractive candidate for COVID-19 patients, and may potentially allow us to prevent or delay their progression to requiring ventilation and intensive care."

Also here is some further info on twitter
https://mobile.twitter.com/AimHardy/status/1306492067183554560
Navigate to his info posted on the the 17th Sept

Hi Dean welcome to DDDD lets focus on the game changing news that could be announced any day now. I received a reply to my email this morning confirming that the results would be published before the end of Q3 for our live bio-therapeutic candidate Blautix for irritable bowel syndrome (IBS). It is looking to address both IBS-Constipation predominant (IBS-C) and IBS-Diarrhoea predominant (IBS-D).

So why is this so game changing well lets take a lot at the below research.
The global irritable bowel syndrome treatment market size was valued at USD 1.5 billion in 2018 and is anticipated to exhibit a CAGR of 10.1% over the forecast period (2020 will ow be over USD 2 billion). Rising prevalence of target disease, coupled with increasing uptake of drugs for the same, is driving the market.
The market mostly remains undeserved, with a considerable number of opportunities for pharmaceutical companies to address several unmet needs in this therapy area. There are a few promising products currently under clinical trials, which can further accelerate growth (this is where we come in) . Product sales are projected to grow significantly over the forecast period, mainly due to increasing prevalent population and commercialization of novel drugs to treat Constipation-predominant irritable bowel syndrome (IBS) Irritable bowel syndrome is one of the most common functional gastrointestinal disorders, with an estimated global prevalence rate of 10-15%. According to the International Foundation for Gastrointestinal Disorders (IFFGD) in 2016, it was estimated that IBS affects around 25-45 million in the U.S. About 2 in 3 IBS patients are female and most people with this condition are under the age of 50.

What does this mean for us well financially lots I have posted a good few examples today if you read back :-)

Then add to that we have already had a very promising result for our Oncology live bio-therapeutic candidate MRx0518 in combination with immune checkpoint inhibitor (ICI) Keytruda relating to advanced or metastatic non-small cell lung cancer, kidney cancer, bladder cancer and melanoma. Where Phase I/II results achieved a disease control rate (DCR) of 42%, with five of 12 patients experiencing a clinically meaningful benefit from the combination. (42% was well above the expected 10% to consider the trial a success) Furthermore this trial is supported by Merck one of the worlds biggest and most innovative Pharma companies. Recruiting for phase II Part B is now under way taking up to 30 additional patients per tumor type.

Furthermore we await progress on our Covid 19 Phase II trial with results expected in Q4. Recruiting has slowed down for this trial with the inevitable controlling measures put in place taking effect on reducing hospitalised patients. However with wave 2 of Covid now firmly in motion we can expect and update on trial completion in the not to distant future I am sure.

Robins you have been very quiet why post on DDDD now?

Terrier on good RNS 250p open on exceptional RNS 300p+

Que I had already confirmed this earlier on today and posted up my reply from 4D. Just 6 days to go could be tomorrow morning ;-)

Just for a comparison on the day of successful Phase III results for Seres the Sp went from 4.64 to 22.70 a factor of 4.89. Now lets say we get 3/5ths of that rise in a single day due too our results only being Phase II but more confidence in the Microbiome sector then that would be a factor of 2.93.

Lets say we have a current Sp of 150p :
150p x 2.93 = 439.50 giving us a mkt cap of (131M shares in issue x 439.50p) £575M Mkt Cap
I don't see this as unreasonable and look forward to it moving towards £1B as we approach Covid 19 results right at the peak of Wave 2.

With a market cap of already £200M the big boys just need good news from the IBS trial before flooding cash in here the rerate will shock many with conservative price estimates.
I stand by my 400p on the day of good news and moving towards 600p before Covid trial results.

141 - 154 within 16 mins trading this bodes very very well for the next few trading sessions.

Its looking good Terrier market has settled after yesterdays hysteria and good Pharmas will continue to shine :-) Bring on the news not long to wait for potential huge returns.

In auction now lets see where it goes.

151 on the ask now and buys continue to flood in people taking positions now with news just around the corner 6 days to go maximum, could be this afternoon or tomorrow morning literally could drop at anytime now.

Wow it moves fast when the buys come in with only 131M shares in issue the Sp will go ballistic on good IBS trial results.

A ton of buys now coming in above the ASK something is going on ...!!!

Dont worry London after news your head will be in the clouds ;-)

No worries Scrambler I did the same for VAL a week ago and also for when we can expect Covid results for our Phase II which they replied Q4 it really is that easy. :-)

On a side note well done to any of you also invested in VAL from the 8-12p levels like myself it really has been a good run I am now riding there on a free carry after derisking before news also due end of Q3.

So for all the doubters I make that a maximum of 6 more trading days until news. :-)

For anyone doubting when news will come I messaged the company about whether we are still on track for news in Q3 or will it run into Q4 here is the response I received. It really is that easy folks rather than pure conjecture on the BBs just email the company direct if you don't believe me.

Dear Mr -------,



Thanks for your enquiry, and continued support of the company.



Previous guidance remains the same – we are on track to deliver topline data for the Blautix Phase II study before the end of Q3.



Best regards,



Investor Relations, 4D pharma plc

So we have 7 trading days left until the end of Q3 hold on to your shares folks.

Supperritch totally agree that we wont be a Covid only stock however it could be a very nice addition to out therapy lineup. If we have both our IBS and Covid results being favorable then I am sure we both agree we will be many multiples of the current SP. ;-)